115 filings
Page 5 of 6
8-K
fbth4z ln409w0qg9
24 Sep 18
Entry into a Material Definitive Agreement
5:27pm
8-K
mmwk47v8ctoxjiqgg776
21 Sep 18
Crispr Therapeutics Announces Proposed Public Offering of Common Shares
4:16pm
8-K
tpyblkm7lyvqy5aiybr
17 Sep 18
CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes
12:00am
8-K
zlbul ab0ioain7f
11 Sep 18
Other Events
12:00am
8-K
q3ncz 6ps
31 Aug 18
Entry into a Material Definitive Agreement
12:00am
8-K
ucbkwt
7 Aug 18
Reports Second Quarter 2018 Financial Results
5:10pm
8-K
0jivwfrfa9zoyr4rfm
1 Jun 18
Departure of Directors or Certain Officers
5:05pm
8-K
k5r97 adyo5esrg
30 May 18
CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug
4:37pm
8-K
zau d7iyy0zy
8 May 18
Reports First Quarter 2018 Financial Results
7:43am
8-K
ogow3b76 2plj9nw7
8 Mar 18
Reports Fourth Quarter and Full Year 2017 Financial Results
12:00am
8-K
kerjx3
5 Jan 18
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
12:00am
8-K
ac5n76gf dlqw
21 Dec 17
CRISPR Therapeutics Announces Appointment of Dr. Rodger Novak as Chairman of the Board
12:00am
8-K
w310uru6
18 Dec 17
Vertex and CRISPR Therapeutics toCo-Develop andCo-Commercialize
12:00am
8-K
a1a268keg4f tnn
7 Dec 17
Other Events
12:00am
8-K
nbnwsebho2uu
13 Nov 17
CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer
12:00am
8-K
hdeji nu41
8 Nov 17
CRISPR Therapeutics Announces Third Quarter 2017 Financial Results
12:00am
8-K
0cc 1voqudpd3vu
7 Nov 17
Other Events
12:00am
8-K
ykhbhsd3endp9t8pvr
2 Oct 17
CRISPR Therapeutics Announces Promotion of
12:00am
8-K
dllmx3cc57g0xrte82b
10 Aug 17
CRISPR Therapeutics Announces Second Quarter 2017 Financial Results
12:00am
8-K
tlvtz5m6sqisu h6itdb
1 Aug 17
CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development
12:00am